Perspectives on PCR-Based Cellular Kinetics and Biodistribution Analysis for Emerging Adoptive Cell Therapies.

Area of Science:

• Cellular therapy
• Immunology
• Molecular biology

Background:

• Chimeric antigen receptor (CAR) T-cell therapies are advancing, with approved treatments for hematological malignancies.
• New CAR T-cell generations aim to expand applications to solid tumors and autoimmune diseases by addressing limitations like safety, relapse, and manufacturing.
• Understanding cellular kinetics and biodistribution is vital for evaluating CAR T-cell therapy efficacy and safety.

Purpose of the Study:

• To discuss the challenges and considerations of PCR-based cellular kinetics and biodistribution assessment for CAR T-cell therapy programs.
• To highlight the importance of these assessments in overcoming current limitations of CAR T-cell therapies.
• To provide insights for supporting emerging adoptive cell therapy programs.

Main Methods:

• Utilizing droplet digital PCR (ddPCR) for sensitive, specific, and reproducible transgene quantification.
• Employing PCR-based methods for cellular kinetics and biodistribution studies.
• Discussing considerations based on program stage, cell type, and target indication.

Main Results:

• Droplet digital PCR offers advantages in sensitivity, specificity, and absolute quantification for transgene analysis.
• PCR-based methods are crucial for understanding the four phases of CAR T-cell behavior: distribution, expansion, contraction, and persistence.
• Unique challenges exist in cellular kinetics and biodistribution studies for CAR T-cell therapy.

Conclusions:

• PCR-based cellular kinetics and biodistribution assessments are essential for the development and optimization of CAR T-cell therapies.
• Addressing the identified challenges is key to advancing CAR T-cell therapy for various indications.
• This assessment strategy supports the progression of emerging adoptive cell therapy programs.